How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors

Internal Medicine Journal

Volumn 42, Issue 11, 2012, Pages 1243-1250

  Brown, S A ^a,b   Barnes, C ^c   Curtin, J ^d   Dunkley, S ^e   Ockelford, P ^f   Phillips, J ^g   Rowell, J ^h   Smith, M ⁱ   Tran, H ^j  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b Pathology Queensland ^*  (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f AUCKLAND CITY HOSPITAL   (New Zealand)

^g WELLINGTON HOSPITAL   (New Zealand)

^h ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

ⁱ CHRISTCHURCH HOSPITAL   (New Zealand)

^j Haemophilia Treatment Centre   (Australia)

more..

Author keywords

Haemophilia A; Haemophilia B; Inhibitor; NovoSeven; Recombinant activated Factor VII

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ADJUVANT THERAPY; ARTICLE; AUSTRALIA; BRAIN HEMORRHAGE; CLINICAL PRACTICE; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG MONITORING; ELDERLY CARE; HEALTH CARE ACCESS; HEMOPHILIA A; HEMOPHILIA B; HOME CARE; HUMAN; IMMUNOLOGICAL TOLERANCE; NEW ZEALAND; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS;

ANTIFIBRINOLYTIC AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FACTOR VIIA; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HUMANS; ISOANTIBODIES; RECOMBINANT PROTEINS; THROMBOEMBOLISM;

EID: 84869795811     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2012.02942.x     Document Type: Article

References (74)

1. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-57.
2. Gouw SC, van den Berg HM, le Cessie S, van der Bom JG. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007; 5: 1383-1390.
3. DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007; 138: 305-315.
4. Kreuz W, Escuriola-Ettingshausen C, Martinez-Saguer I, Gungor T, Kornhuber B. Epidemiology of inhibitors in haemophilia A. Vox Sang 1996; 70(Suppl 1): 2-8.
5. Peerlinck K, Hermans C. Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy. Haemophilia 2006; 12: 579-590.
6. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 5: 145-154.
7. Hedner U, Lee CA. First 20 years with recombinant FVIIa (NovoSeven). Haemophilia 2011; 17: e172-182.
8. Ø) RT Australian Approved Product Information. 18 August 2008.
9. Australian Haemophilia Centre Directors' Organisation (AHCDO). Guidelines for the treatment of inhibitors in haemophilia A and haemophilia B. Melbourne, Vic.: The Institute; 2010.
10. Abshire T. Safety update on recombinant factor VIIa in the treatment of congenital and acquired hemophilia. Semin Hematol 2008; 45: S3-6.
11. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
12. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295: 293-298.
13. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858-3864.
14. Butros L, Boayue K, Mathew P. Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa. Drug Des Devel Ther 2011; 5: 275-282.
15. Bysted BV, Scharling B, Moller T, Hansen BL. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation. Haemophilia 2007; 13: 527-532.
16. Nedergaard H, Vestergaard S, Jensen PT, Kristiansen MW, Jensen MB, Østergaard PB etal. In vitro stability of lyophilized and reconstituted recombinant activated factor VII formulated for storage at room temperature. Clin Ther 2008; 30: 1309-1315.
17. Escobar MA. Health economics in haemophilia: a review from the clinician's perspective. Haemophilia 2010; 16(Suppl 3): 29-34.
18. Kissela BM, Eckman MH. Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage. BMC Neurol 2008; 8: 17. doi:10.1186/1471-2377-8-17.
19. Ekert H, Brewin T, Boey W, Davey P, Tilden D. Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX. Haemophilia 2001; 7: 279-285.
20. Ballal RD, Botteman MF, Foley I, Stephens JM, Wilke CT, Joshi AV. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling. Curr Med Res Opin 2008; 24: 753-768.
21. Lyseng-Williamson KA, Plosker GL. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX. Pharmacoeconomics 2007; 25: 1007-1029.
22. Hay JW, Zhou ZY. Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors. Haemophilia 2011; 17: e969-974.
23. Berntorp E. Importance of rapid bleeding control in haemophilia complicated by inhibitors. Haemophilia 2011; 17: 11-16.
24. Lusher JM, Roberts HR, Davignon G, Joist JH, Smith H, Shapiro A etal. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 1998; 4: 790-798.
25. Salaj P, Brabec P, Penka M, Pohlreichova V, Smejkal P, Cetkovsky P etal. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia 2009; 15: 752-759.
26. Treur MJ, McCracken F, Heeg B, Joshi AV, Botteman MF, De Charro F etal. Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression. Haemophilia 2009; 15: 420-436.
27. Medical Advisory Committee of Haemophilia Foundation of New Zealand. National guidelines: management of haemophilia - treatment protocols. Christchurch: Haemophilia Foundation of New Zealand; 2005.
28. Villar A, Aronis S, Morfini M, Santagostino E, Auerswald G, Thomsen HF etal. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004; 10: 352-359.
29. Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006; 95: 600-605.
30. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 367-371.
31. Young G, Shafer FE, Rojas P, Seremetis S. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008; 14: 287-294.
32. Almagro D, Agramonte O, Castillo D, Zamora Y, Ballester JM. Experience with a single dose of recombinant activated factor VII for the management of mild-to-moderate bleeds in haemophilia. Haemophilia 2011; 17: 322-323.
33. Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-106.
34. Neufeld EJ, Kessler CM, Gill JC, Wilke CT, Cooper DL. Exposure and safety of higher doses of recombinant factor VIIa >/=250 mug kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008). Haemophilia 2011; 17: 650-656.
35. Berntorp E, Astermark J, Bjorkman S, Blanchette VS, Fischer K, Giangrande PLF etal. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9(Suppl 1): 1-4.
36. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R etal. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-544.
37. Smith PS, Teutsch SM, Shaffer PA, Rolka H, Evatt B. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. J Pediatr 1996; 129: 424-431.
38. Hoots WK, Ebbesen LS, Konkle BA, Auerswald GK-H, Roberts HR, Weatherall J etal. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 2008; 14: 466-475.
39. Auerswald G, Morfini M. Prophylaxis with recombinant activated Factor VII in hemophilia patients with inhibitors. J Coagul Disord 2010; 2: 1-8.
40. Carcao M, Lambert T. Prophylaxis in haemophilia with inhibitors: update from international experience. Haemophilia 2010; 16(Suppl 2): 16-23.
41. Perry D, Berntorp E, Tait C, Dolan G, Holme PA, Laffan M etal. FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations. Haemophilia 2010; 16: 80-89.
42. Konkle BA, Ebbesen LS, Erhardtsen E, Bianco RP, Lissitchkov T, Rusen L etal. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-1913.
43. Morfini M, Haya S, Tagariello G, Rivolta GF, Rodriguez-Martorell J, Scaraggi FA etal. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-612.
44. Kubisz P, Plamenova I, Stasko J, Dobrotova M, Holly P. Long-term secondary prophylaxis with recombinant activated factor VII (rFVIIa) in haemophilia A with inhibitors: a case report. Thromb Haemost 2010; 103: 868-870.
45. Hedner U. Potential role of recombinant factor FVIIa in prophylaxis in severe hemophilia patients with inhibitors. J Thromb Haemost 2006; 4: 2498-2500.
46. Young G, Blain R, Nakagawa P, Nugent DJ. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia 2006; 12: 598-604.
47. Lopez-Vilchez I, Tusell J, Hedner U, Altisent C, Escolar G, Galan AM. Redistribution of recombinant activated factor VIIa into platelets and vascular bed: implications on hemostatic mechanisms. J Thromb Haemost 2009; 7(Suppl 2): 317-1168. (poster: PP-WE-237).
48. Lopez-Vilchez I, Tussell J, Hedner U, Altisent C, Escolar G, Galan AM. Traffic of rFVIIa through endothelial cells and redistribution into subendothelium: implications for a prolonged hemostatic effect. J Coagul Disord 2009; 1: 1-6.
49. Gopalakrishnan R, Hedner U, Clark C, Pendurthi UR, Rao LV. rFVIIa transported from the blood stream into tissues is functionally active. J Thromb Haemost 2010; 8: 2318-2321.
50. Giangrande PL, Wilde JT, Madan B, Ludlam CA, Tuddenham GD, Goddard NJ etal. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia 2009; 15: 501-508.
51. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-778.
52. Valentino LA, Cooper DL, Goldstein B. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX. Haemophilia 2011; 17: 579-589.
53. Pruthi RK, Mathew P, Valentino LA, Sumner MJ, Seremetis S, Hoots WK. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial. Thromb Haemost 2007; 98: 726-732.
54. Franchini M, Mannucci PM. Co-morbidities and quality of life in elderly persons with haemophilia. Br J Haematol 2010; 148: 522-533.
55. Arkin S, Cooper HA, Hutter JJ, Miller S, Schmidt ML, Seibel NL etal. Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the novoseven emergency-use program. Haemostasis 1998; 28: 93-98.
56. Nakar C, Cooper DL, DiMichele D. Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia and Thrombosis Research Society Registry (2004-2008). Haemophilia 2010; 16: 625-631.
57. Young G, Auerswald G, Jimenez-Yuste V, Konkle BA, Lambert T, Morfini M etal. When should prophylaxis therapy in inhibitor patients be considered? Haemophilia 2011; 17: e849-857.
58. Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 2004; 77: 187-193.
59. Cooper HA, Jones CP, Campion E, Roberts HR, Hedner U. Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia 2001; 7: 517-522.
60. Salek SZ, Benson GM, Elezovic I, Krenn V, Ljung RC, Morfini M etal. The need for speed in the management of haemophilia patients with inhibitors. Haemophilia 2011; 17: 95-102.
61. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM etal. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-918.
62. World Federation of Hemophilia. Guidelines for the management of hemophilia. 2005. Available from http://wfh.org/2/7/7_0_Publications.htm
63. European Medicines Agency. European public assessment reports: NovoSeven summary of product characteristics. last update: 02/03/2012. Available from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000074/human_med_000936.jsp&mid=WC0b01ac058001d124&murl=menus/medicines/medicines.jsp
64. Giangrande PL, Escobar MA. Management of difficult-to-treat inhibitor patients. Haemophilia 2010; 16(Suppl 3): 52-57.
65. Teitel J, Berntorp E, Collins P, D'Oiron R, Ewenstein B, Gomperts E etal. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 2007; 13: 256-263.
66. Berntorp E, Collins P, d'Oiron R, Ewing N, Gringeri A, Negrier C etal. Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition. Haemophilia 2011; 17: e202-210.
67. Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 2010; 116: 5734-5737.
68. Kenet G, Stenmo CB, Blemings A, Wegert W, Goudemand J, Krause M etal. Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial. Thromb Haemost 2010; 103: 351-359.
69. Schulman S, d'Oiron R, Martinowitz U, Pasi J, Briquel ME, Mauser-Bunschoten E etal. Experiences with continuous infusion of recombinant activated factor VII. Blood Coagul Fibrinolysis 1998; 9(Suppl 1): S97-101.
70. Hvid I, Rodriguez-Merchan EC. Orthopaedic surgery in haemophilic patients with inhibitors: an overview. Haemophilia 2002; 8: 288-291.
71. Rodriguez-Merchan EC, Wiedel JD, Wallny T, Hvid I, Berntorp E, Rivard G-E etal. Elective orthopaedic surgery for inhibitor patients. Haemophilia 2003; 9: 625-631.
72. Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia 2008; 14: 898-902.
73. Schneiderman J, Rubin E, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007; 13: 244-248.
74. Petersson B, Schonwandt AB, Thornstfeldt P, Nedergaard H, Bech Jensen M, Ostergaard PB etal. In vitro stability of two formulations of recombinant activated factor VIIa reconstituted in inappropriate solvents or at inappropriate volumes. Clin Ther 2008; 30: 917-923.